Mitochondrial Disease Externally-led Patient-Focused Drug Development Meeting
March 29, 2019
COLLEGE PARK MARRIOTT HOTEL & CONFERENCE CENTER
A special, discounted room rate is available for attendees. Make your hotel reservations here.
Join us for this groundbreaking meeting to share YOUR experiences living with mitochondrial disease with the Food and Drug Administration (FDA) and other drug development stakeholders.
Among the many responsibilities of the FDA is to protect the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices.
Through this EL-PFDD, YOU can help educate the FDA about:
- What it is like to live with a mitochondrial disease
- Your concerns as the disease progresses
- How you currently manage your mitochondrial disease
- What meaningful treatments look like
This is an opportunity to have YOUR VOICES heard.
ALL PATIENTS, FAMILIES, AND CAREGIVERS ARE INVITED TO PARTICIPATE!
Individuals living with mitochondrial disease and their caregivers and family members are invited to participate. Everyone who attends the meeting will have a chance to share his or her experiences and perspectives. If you cannot attend in person, you can stream the meeting online where you can participate in live polling throughout the day. Your input, both in-person or online, will be heard by FDA officials attending the meeting and will also be summarized in a report to the FDA. We will also send you surveys and other communications so that we can help you contribute your thoughts. Sign up to receive these monthly e-communications!
What is an Externally-led Patient-Focused Drug Development Meeting?
The patient perspective is critical in helping FDA understand the context in which regulatory decisions are made for new drugs. Externally-led PFDD meetings give FDA an important opportunity to hear directly from patients, patient advocates, and caretakers about the symptoms that matter most to them, the impact the disease has on patients’ daily lives, and patients’ experiences with currently available treatments. This input can inform FDA’s decisions and oversight both during drug development and during review of a marketing application. UMDF, in collaboration with the Muscular Dystrophy Association, MitoAction and the Foundation for Mitochondrial Medicine, is excited to host this Externally-led Patient-Focused Drug Development meeting for the mitochondrial disease community on March 29, 2019!
How is this meeting designed for YOU to be heard by FDA?
This Externally-led Patient Focused Drug Development meeting will use multiple methods for soliciting YOUR thoughts and experiences about living with mitochondrial disease. EVERYONE who attends will have a chance to be part of the conversation. To allow us to hear as many different perspectives as possible, we have four main areas of focus for our panels – Burdens of the Disease for Pediatric Mitochondrial Disease Patients with Neurologic Manifestations and Adult Patients with Mitochondrial Myopathies and Management of Care for Pediatric Mitochondrial Disease Patients with Neurologic Manifestations and Adult Patients with Mitochondrial Myopathies. Following opening remarks by FDA officials and others, each session will include panel discussions made up of patients and family members. Mitochondrial disease patient advocacy groups invited members of the community that reflect the diversity of mitochondrial disease experiences to be a panelist or a speaker. After the panels, everyone in the audience in-person or online will be able to answer live polling questions and we will be able to see the results in real time. In addition, all of YOU that can attend in-person will be invited to be part of a live discussion in the room where you can share your own experiences. The meeting will be ‘live streamed’ online, too, for those who cannot attend in person. Select representatives of associated drug development stakeholders (researchers, clinicians, industry) will be invited to attend as well or may join the streamed presentation. After the meeting, all of this input, along with information collected prior to and after the meeting, will be summarized as a “Voice of the Patient” report, which our community will be submitting to FDA.
Why is this Externally Led Patient Focused Drug Development meeting important for OUR community?
For the mitochondrial disease community, this meeting is the first opportunity for a group of patients, families and other caregivers to speak directly to the FDA, and to share their experiences in their own words. It is also the first time a report on the patient experience will be completed and shared with the FDA. This input can inform FDA’s decisions and oversight both during drug development and during review of a marketing application. We need YOUR participation to make sure our collective community voice makes a positive impact.